[Tai Tsung] Announcement of the Company's Subscription to Private Placement Ordinary Shares of Xiangyi Pharmaceutical Co., Ltd.
NQ Score
0/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 million private placement ordinary shares for a maximum of NT$240 million. This will result in Tai Tsung holding an 11.79% stake in Xiangyi, accounting for 19.35% of its total assets and 22.74% of equity attributable to the parent company. An accountant has expressed a non-reasonable opinion on the transaction.